前列腺癌立体定向体部放疗的肿瘤控制概率建模与系统综述
低-中危患者EQD2 71 Gy(5次31.7 Gy)可达90% TCP,EQD2 90 Gy(5次36.1 Gy)可达95% TCP;高危患者EQD2 97 Gy(5次37.6 Gy)可达90% TCP,EQD2 102 Gy(5次38.7 Gy)可达95% TCP。
要点
- 低-中危前列腺癌SBRT:EQD2 71 Gy(5次31.7 Gy)TCP达90%,EQD2 90 Gy(5次36.1 Gy)TCP达95%。
- 高危前列腺癌SBRT:EQD2 97 Gy(5次37.6 Gy)TCP达90%,EQD2 102 Gy(5次38.7 Gy)TCP达95%。
- 多数处方剂量为35–40 Gy分4–5次,文献在靶区勾画、 margins、剂量分割和疗程上差异显著。
核心结论
- 尽管文献在靶区勾画、 margins、剂量分割和疗程上存在显著差异,SBRT的TCP表现优异。
研究设计与样本
- 美国医学物理学家协会(AAPM)关于大分割放疗/SBRT生物学效应的工作组下设亚组,系统综述文献并建立前列腺癌SBRT的剂量-反应TCP模型,终点为生化复发自由度。
主要发现
- 5项研究的中位随访超过5年。
- 剂量方案范围为4–5次32–50 Gy,总BED(α/β=1.5 Gy)在183.1至383.3 Gy之间。
- 5年时,低-中危患者EQD2 71 Gy(5次31.7 Gy)TCP达90%,EQD2 90 Gy(5次36.1 Gy)TCP达95%。
- 高危患者EQD2 97 Gy(5次37.6 Gy)TCP达90%,EQD2 102 Gy(5次38.7 Gy)TCP达95%。
关键数值与推荐
- 低-中危前列腺癌:EQD2 71 Gy(5次31.7 Gy)对应TCP 90%,EQD2 90 Gy(5次36.1 Gy)对应TCP 95%。
- 高危前列腺癌:EQD2 97 Gy(5次37.6 Gy)对应TCP 90%,EQD2 102 Gy(5次38.7 Gy)对应TCP 95%。
- 多数处方剂量范围为35–40 Gy,分4–5次给予。
临床怎么用
- 对于低-中危前列腺癌,SBRT处方EQD2约71 Gy(5次31.7 Gy)可预期90%的5年生化控制概率。
- 对于高危前列腺癌,需更高EQD2(约97 Gy,5次37.6 Gy)才能达到90%的5年生化控制概率。
- 多数临床SBRT方案采用35–40 Gy分4–5次,与模型预测的TCP范围一致。
局限性
- 文献未提供详细的剂量-体积数据,剂量学分析仅限于处方剂量。
- 已发表文献在靶区勾画、 margins、剂量/分割和疗程上存在显著差异。
- 需要更长随访来评估各风险组的局部控制持久性、SBRT作为IMRT推量的疗效与安全性,以及新型成像技术融入治疗计划的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Dose escalation improves localized prostate cancer disease control, and moderately hypofractionated external beam radiation is noninferior to conventional fractionation. The evolving treatment approach of ultrahypofractionation with stereotactic body radiation therapy (SBRT) allows possible further biological dose escalation (biologically equivalent dose [BED]) and shortened treatment time. METHODS AND MATERIALS: The American Association of Physicists in Medicine Working Group on Biological Effects of Hypofractionated Radiation Therapy/SBRT included a subgroup to study the prostate tumor control probability (TCP) with SBRT. We performed a systematic review of the available literature and created a dose-response TCP model for the endpoint of freedom from biochemical relapse. Results were stratified by prostate cancer risk group. RESULTS: Twenty-five published cohorts were identified for inclusion, with a total of 4821 patients (2235 with low-risk, 1894 with intermediate-risk, and 446 with high-risk disease, when reported) treated with a variety of dose/fractionation schemes, permitting dose-response modeling. Five studies had a median follow-up of more than 5 years. Dosing regimens ranged from 32 to 50 Gy in 4 to 5 fractions, with total BED (α/β = 1.5 Gy) between 183.1 and 383.3 Gy. At 5 years, we found that in patients with low-intermediate risk disease, an equivalent doses of 2 Gy per fraction (EQD2) of 71 Gy (31.7 Gy in 5 fractions) achieved a TCP of 90% and an EQD2 of 90 Gy (36.1 Gy in 5 fractions) achieved a TCP of 95%. In patients with high-risk disease, an EQD2 of 97 Gy (37.6 Gy in 5 fractions) can achieve a TCP of 90% and an EQD2 of 102 Gy (38.7 Gy in 5 fractions) can achieve a TCP of 95%. CONCLUSIONS: We found significant variation in the published literature on target delineation, margins used, dose/fractionation, and treatment schedule. Despite this variation, TCP was excellent. Most prescription doses range from 35 to 40 Gy, delivered in 4 to 5 fractions. The literature did not provide detailed dose-volume data, and our dosimetric analysis was constrained to prescription doses. There are many areas in need of continued research as SBRT continues to evolve as a treatment modality for prostate cancer, including the durability of local control with longer follow-up across risk groups, the efficacy and safety of SBRT as a boost to intensity modulated radiation therapy (IMRT), and the impact of incorporating novel imaging techniques into treatment planning.
引用
- Royce TJ, Mavroidis P, Wang K, et al. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32900561. doi:10.1016/j.ijrobp.2020.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。